Recent News

• 11.10.2025 - CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.08.2025 - CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
• 10.10.2025 - CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
• 10.01.2025 - CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
• 10.01.2025 - CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
• 10.01.2025 - CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
• 09.22.2025 - CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

Recent Filings

• 11.10.2025 - 8-K Current report
• 11.10.2025 - EX-99.1 EX-99.1
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.15.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.15.2025 - 8-K Current report
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities